Hims & Hers Health (HIMS) Stock Price, News & Analysis

Company Overview

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Key Stats

• Today's Range: $61.52 to $64.60
• 50-Day Range: $25.41 to $64.47
• 52-Week Range: $13.47 to $72.98
• Volume: 42.12 million shs
• Average Volume: 21.60 million shs
• Market Capitalization: $14.43 billion
• P/E Ratio: 93.44
• Dividend Yield: N/A
• Price Target: $38.00
• Consensus Rating: Hold

Hims & Hers Health Stock Analysis - MarketRank™

Hims & Hers Health scored higher than 50% of companies evaluated by MarketBeat, and ranked 510th out of 924 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Hold

Consensus Rating

Hims & Hers Health has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on 3 buy ratings, 8 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

Hims & Hers Health has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 79.31%

Earnings Growth

Earnings for Hims & Hers Health are expected to grow by 79.31% in the coming year, from $0.29 to $0.52 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Hims & Hers Health is 93.44, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.18.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hims & Hers Health is 93.44, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 19.20.

Price to Earnings Growth Ratio

Hims & Hers Health has a PEG Ratio of 2.42. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Hims & Hers Health has a P/B Ratio of 29.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

33.86% of the float of Hims & Hers Health has been sold short.

Short Interest Ratio / Days to Cover

Hims & Hers Health has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hims & Hers Health has recently decreased by 2.34%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hims & Hers Health does not currently pay a dividend.

Dividend Growth

Hims & Hers Health does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

33.86% of the float of Hims & Hers Health has been sold short.

Short Interest Ratio / Days to Cover

Hims & Hers Health has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hims & Hers Health has recently decreased by 2.34%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.53

News Sentiment

Hims & Hers Health has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 35 news articles for Hims & Hers Health this week, compared to 23 articles on an average week.

Search Interest

Only 139 people have searched for HIMS on MarketBeat in the last 30 days. This is a decrease of -46% compared to the previous 30 days.

MarketBeat Follows

Only 46 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -39% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Hims & Hers Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,486,522.00 in company stock.

Percentage Held by Insiders

17.71% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

63.52% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HIMS Stock Analysis - Frequently Asked Questions

How have HIMS shares performed this year?

Hims & Hers Health's stock was trading at $24.18 at the start of the year. Since then, HIMS shares have increased by 166.6% and is now trading at $64.4730.
View the best growth stocks for 2025 here.

How were Hims & Hers Health's earnings last quarter?

Hims & Hers Health, Inc. (NYSE:HIMS) announced its quarterly earnings data on Monday, May, 5th. The company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. The company's revenue for the quarter was up 110.7% compared to the same quarter last year.
Read the conference call transcript.

Who are Hims & Hers Health's major shareholders?

Hims & Hers Health's top institutional investors include Vanguard Group Inc. (8.32%), Northern Trust Corp (1.09%), Yong Rong HK Asset Management Ltd (1.08%) and Nuveen LLC (0.88%). Insiders that own company stock include Melissa Baird, David B Wells, Alex Bard, Michael Chi, Patrick Harrison Carroll, Soleil Boughton, Christopher D Payne, Andrew Dudum, Oluyemi Okupe, Christiane Pendarvis, Anja Manuel, Irene Becklund, Irene Becklund and Lynne Chou O'keefe.
View institutional ownership trends.

How do I buy shares of Hims & Hers Health?

Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Hims & Hers Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Hims & Hers Health investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 5/05/2025
• Today: 6/22/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Healthcare
• Current Symbol: NYSE:HIMS
• CIK: 1773751
• Web: www.forhims.com
• Phone: 415-851-0195
• Fax: N/A
• Employees: 1,637
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $38.00
• High Stock Price Target: $68.00
• Low Stock Price Target: $23.00
• Potential Upside/Downside: -41.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.08
• Research Coverage: 13 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.69
• Trailing P/E Ratio: 93.44
• Forward P/E Ratio: 222.32
• P/E Growth: 2.42
• Net Income: $126.04 million
• Net Margins: 9.24%
• Pretax Margin: 6.71%
• Return on Equity: 22.75%
• Return on Assets: 15.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.59
• Quick Ratio: 1.32

Sales & Book Value

• Annual Sales: $1.48 billion
• Price / Sales: 9.77
• Cash Flow: $0.35 per share
• Price / Cash Flow: 182.36
• Book Value: $2.16 per share
• Price / Book: 29.85

Miscellaneous

• Outstanding Shares: 223,830,000
• Free Float: 193,145,000
• Market Cap: $14.43 billion
• Optionable: Optionable
• Beta: 2.09